Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Q2 2020 Earnings Presentation
14 slides from Theravance Biopharma's earnings presentation, Aug 6, 2020
Slide 1: Second Quarter 2020 Financial Results and Business Update
Second Quarter 2020 Financial Results and Business Update August 6, 2020 THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies. All third party trademarks used herein are the property of their respective owne
Slide 2: Forward-looking statements
Forward - looking statements 2 Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may cause actual resul
Slide 3: Q2 Financial results and business update agenda
Q2 Financial results and business update agenda 3 Introduction Gail B. Cohen Vice President, Corporate Communications & Investor Relations Overview Rick E Winningham Chief Executive Officer Commercial and Development Update Frank Pasqualone Senior Vice President, Chief Commercial Operations Officer
Slide 4: YUPELRI inhalation solution
YUPELRI ® (revefenacin) inhalation solution First and only once - daily, nebulized maintenance medicine for COPD
Slide 5: First and only once-daily, nebulized maintenance medicine for COPD
First and only once - daily, nebulized maintenance medicine for COPD YUPELRI ® (revefenacin) inhalation solution FDA - approved for the maintenance treatment of COPD 1. Global Strategy for Diagnosis, Management, and Prevention of COPD, 2018; 2. TBPH market research (N = 160 physicians); ref ers to U
Slide 6: YUPELRI launch metrics and access
Majority of YUPELRI ® volume flows through durable medical equipment channel (approximately 3 - month lag in data capture); remaining volume flows thro ugh hospitals, retail and long - term care pharmacies. Wholesale acquisition cost (WAC): $1,066 per month (or ~$35 per day). 1. As of June 30, 2020.
Slide 7: Key programs supported by proven development and commercial expertise
Program Indication Research Phase 1 Phase 2 Phase 3 Filed Marketed Collaborator YUPELRI ® (revefenacin) LAMA COPD Ampreloxetine (TD - 9855) NRI S ymptomatic nOH Wholly - owned Organ - selective TD - 1473 GI JAKi UC CD TD - 5202 Irreversible JAK3i Inflammatory intestinal diseases TD - 8236 Inhaled JA
Slide 8: Economic interest in GSK's TRELEGY
Economic interest GSK’s TRELEGY (FF/UMEC/VI): First and only once - daily single inhaler triple therapy
Slide 9: Economic interest in GSK's TRELEGY
Economic interest in GSK’s TRELEGY Upward - tiering royalties of ~5.5 – 8.5% of worldwide net sales 1 Q2 net sales of £194m (or $241M) Grew market share with sales up 58% US asthma approval continues to be expected 2H 20 1. TBPH holds 85% economic interest in upward - tiering royalty stream of 6.5%
Slide 10: Second quarter 2020 financial highlights
Second quarter 2020 financial highlights Well capitalized with $438.3m 1 as of June 30, 2020 1 Cash, cash equivalents and marketable securities. 2 Amounts include share - based compensation. 10 ($, in thousands) Revenue: Collaboration revenue $ 5,488 $ 7,493 $ 12,120 $ 12,831 Licensing revenue - 18,
Slide 11: Multiple potential milestones and value-driving catalysts
GSK’s TRELEGY 1 ‣ FDA decision for asthma and separately for mortality benefit vs. ANORO in COPD TD - 8236 ‣ Phase 1 Part C data in moderate to severe asthmatics ‣ Phase 2 allergen challenge data Ampreloxetine ‣ Phase 3 4 - week efficacy data TD - 1473 ‣ Phase 2b/3 ulcerative colitis data ‣ Phase 2
Slide 12: In conclusion
In conclusion 12 Theravance Biopharma’s commitment to our mission, to transform the treatment of serious diseases through the discovery, development, and commercialization of organ - selective medicines designed to maximize patient benefit while minimizing patient risk… has never been stronger.
Slide 13: About YUPELRI inhalation solution
About YUPELRI ® (revefenacin) inhalation solution YUPELRI ® (revefenacin) inhalation solution is a once - daily nebulized LAMA approved for the maintenance treatment of COPD in the US . Market research by Theravance Biopharma indicates approximately 9 % of the treated COPD patients in the US use neb
Slide 14: YUPELRI indication and Important Safety Information
YUPELRI ® (revefenacin) inhalation solution YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . Important Safety Information (US) YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any com